Neurosarcoidosis

Current Treatment Options in Neurology

Volumn 15, Issue 4, 2013, Pages 492-504

  Nozaki, Kenkichi ^a   Judson, Marc A ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Chloroquine; Corticosteroids; Cyclophosphamide; Hydroxychloroquine; Infliximab; Methotrexate; Neurosarcoidosis; Treatment

Indexed keywords

ADALIMUMAB; ANTICONVULSIVE AGENT; ARTEMETHER; AZATHIOPRINE; BCG VACCINE; BENFLUMETOL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETIRACETAM; ETRETIN; GALLIUM 67; HYDROXYCHLOROQUINE; INFLIXIMAB; LIVE VACCINE; MEFLOQUINE; METHOTREXATE; METHYLPREDNISOLONE; MIFEPRISTONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PENTOXIFYLLINE; PIMECROLIMUS; PREDNISOLONE; PREDNISONE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; BLADDER CANCER; BONE MARROW SUPPRESSION; BRAIN BIOPSY; CARCINOGENICITY; CARDIOTOXICITY; CATARACT; CEREBROSPINAL FLUID ANALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CORTICOSTEROID INDUCED MYOPATHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEMYELINATING DISEASE; DEMYELINATION; DIFFERENTIAL DIAGNOSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; EDEMA; EPILEPSY; EYE TOXICITY; GASTRITIS; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GLUCOSE INTOLERANCE; HEARING IMPAIRMENT; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; HYDROCEPHALUS; HYPERTENSION; INFECTION; INFERTILITY; INSOMNIA; INTRACRANIAL HYPERTENSION; KIDNEY FAILURE; LETHARGY; LEUKEMIA; LIVER DISEASE; LIVER TOXICITY; LOADING DRUG DOSE; LUPUS ERYTHEMATOSUS; MALIGNANT NEOPLASTIC DISEASE; MOOD CHANGE; MULTIPLE SCLEROSIS; MYOPATHY; NEUROENDOCRINE DISEASE; NEUROIMAGING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PEPTIC ULCER; PNEUMONIA; PSYCHOSIS; RETINA DISEASE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEIZURE; SIDE EFFECT; SPINAL CORD COMPRESSION; TERATOGENICITY; UREMIA; WOUND HEALING IMPAIRMENT;

EID: 84882283252     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-013-0242-9     Document Type: Article

References (63)

1. Judson MA. Sarcoidosis: clinical presentation, diagnosis, and approach to treatment. Am J Med Sci. 2008;335(1):26-33.
2. Chen RC, McLeod JG. Neurological complications of sarcoidosis. Clin Exp Neurol. 1989;26:99-112.
3. Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909-17.
4. Delaney P. Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med. 1977;87(3):336-45.
5. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997;157(16):1864-8.
6. Gullapalli D, Phillips II LH. Neurosarcoidosis. Curr Neurol Neurosc Rep. 2004;4(6):441-7.
7. Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(2):118-25.
8. Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, et al. Neurosarcoidosis: presentations and management. Neurologist. 2010;16(1):2-15.
9. Brouwer MC, de Gans J, Willemse RB, van de Beek D. Neurological picture. Sarcoidosis presenting with hydrocephalus. J Neurol Neurosurg Psychiatr. 2009;80(5):550-1.
10. Westhout FD, Linskey ME. Obstructive hydrocephalus and progressive psychosis: rare presentations of neurosarcoidosis. Surg Neurol. 2008;69(3):288-92. discussion 292.
11. Benzagmout M, Boujraf S, Gongora-Rivera F, Bresson D, Van-Effenterre R. Neurosarcoidosis which manifested as acute hydrocephalus: diagnosis and treatment. Intern Med. 2007;46(18):1601-4.
12. Varron L, Broussolle C, Candessanche JP, Marignier R, Rousset H, Ninet J, et al. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol. 2009;16(3):289-96.
13. Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol. 2007;64(5):691-6.
14. Rudkin AK, Wilcox RA, Slee M, Kupa A, Thyagarajan D. Relapsing encephalopathy with headache: an unusual presentation of isolated intracranial neurosarcoidosis. J Neurol Neurosurg Psychiatr. 2007;78(7):770-1.
15. Krumholz A, Stern BJ, Stern EG. Clinical implications of seizures in neurosarcoidosis. Arch Neurol. 1991;48(8):842-4.
16. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125(3):997-1004.
17. Chang B, Steimel J, Moller DR, Baughman RP, Judson MA, Yeager Jr H, et al. Depression in sarcoidosis. Am J Resp Crit Care Med. 2001;163(2):329-34.
18. Porter N, Beynon HL, Randeva HS. Endocrine and reproductive manifestations of sarcoidosis. QJM. 2003;96(8):553-61.
19. Langrand C, Bihan H, Raverot G, Varron L, Androdias G, Borson-Chazot F, et al. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM. 2012;105(10):981-95.
20. Vital A, Lagueny A, Ferrer X, Louiset P, Canron MH, Vital C. Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature. Clin Neuropath. 2008;27(2):96-105.
21. Oldroyd A, Dawson T, Nixon J. A case of neurosarcoidosis that presented with symptoms of Guillain-Barre syndrome. BMJ Case Rep. 2011.
22. Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep. 2011;15(3):201-6. This article is a thorough review of small fiber neuropathy in sarcoidosis.
23. Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Op Pulm Med. 2010;16(5):472-9.
24. Reulen JP, Lansbergen MD, Verstraete E, Spaans F. Comparison of thermal threshold tests to assess small nerve fiber function: limits vs levels. Clin Neurophysiol. 2003;114(3):556-63.
25. Truini A, Galeotti F, Romaniello A, Virtuoso M, Iannetti GD, Cruccu G. Laser-evoked potentials: normative values. Clin Neurophysiol. 2005;116(4):821-6.
26. Atherton DD, Facer P, Roberts KM, Misra VP, Chizh BA, Bountra C, et al. Use of the novel Contact Heat Evoked Potential Stimulator (CHEPS) for the assessment of small fiber neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts. BMC Neurol. 2007;7:21.
27. Low PA, Caskey PE, Tuck RR, Fealey RD, Dyck PJ. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann Neurol. 1983;14(5):573-80.
28. Ferriby D, de Seze J, Stojkovic T, Hachulla E, Wallaert B, Destee A, et al. Long-term follow-up of neurosarcoidosis. Neurology. 2001;57(5):927-9.
29. Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatr. 2009;80(3):297-304.
30. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Resp Crit Care Med. 1999;160(2):736-55.
31. Nozaki K, Judson MA. Neurosarcoidosis: clinical manifestations, diagnosis and treatment. Presse Med. 2012;41(6 Pt 2):e331-348. This article provides the most current and comprehensive review of neurosarcoidosis.
32. Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest. 1997;112(1):220-8.
33. Nozaki K, Scott TF, Sohn M, Judson MA. Isolated neurosarcoidosis: case series in 2 sarcoidosis centers. Neurologist. 2012;18(6):373-7. This is the largest case series of isolated neurosarcoidosis.
34. Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. Am J Radiol. 2004;182(2):289-95.
35. Pickuth D, Heywang-Kobrunner SH. Neurosarcoidosis: evaluation with MRI. J Neurradiol. 2000;27(3):185-8.
36. Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K. Spinal cord neurosarcoidosis. Am J Med Sci. (in press).This case series describes a large number of diverse manifestations of spinal neurosarcoidosis. Class IV evidence.
37. Tartaglino LM, Friedman DP, Flanders AE, Lublin FD, Knobler RL, Liem M. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology. 1995;195(3):725-32.
38. Khoury J, Wellik KE, Demaerschalk BM, Wingerchuk DM. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis. Neurologist. 2009;15(2):108-11.
39. Dale JC, O'Brien JF. Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc. 1999;74(5):535. Erratum in Mayo Clin Proc. 2000;75(3):318.
40. Tahmoush AJ, Amir MS, Connor WW, Farry JK, Didato S, Ulhoa-Cintra A, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):191-7.
41. Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest. 2003;124(5):2023-6. Class IV evidence
42. Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol. 1995;52(9):875-9.
43. Marangoni S, Argentiero V, Tavolato B. Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol. 2006;253(4):488-95.
44. Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis-diagnosis and management. QJM. 1999;92(2):103-17.
45. Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med. 2009;103(2):268-73. Class IV evidence.
46. UpToDate: http://www.uptodate.com/home. In: Wolters Kluwer Health.
47. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide vs daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthr Rheum. 1998;41(10):1835-44. Class II evidence.
48. Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Class IV evidence. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(1):87-92.
49. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14(5):1117-22. Class IV evidence.
50. Corbett J. Treating CNS, sarcoidosis with infliximab and mycophenolate mofetil. Curr Neurol Neurosci Rep. 2009;9(5):339-40. Class IV evidence.
51. Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009;72(4):337-40. Class IV evidence.
52. Chaussenot A, Bourg V, Chanalet S, Fornari JM, Lebrun C. [Neurosarcoidosis treated with mycophenolate mofetil: two cases]. Rev Neurol (Paris). 2007;163(4):471-5. Class IV evidence.
53. Androdias G, Maillet D, Marignier R, Pinede L, Confavreux C, Broussolle C, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. 2011;76(13):1168-72. Class IV evidence.
54. Santos E, Shaunak S, Renowden SA, Scolding NJ. Treatment of refractory neurosarcoidosis with infliximab. Class IV evidence. J Neurol Neurosurg Psychiatr. 2010;81(3):241-6.
55. Pereira J, Anderson NE, McAuley D, Bergin P, Kilfoyle D, Fink J. Medically refractory neurosarcoidosis treated with infliximab. Class IV evidence. Intern Med J. 2011;41(4):354-7.
56. Chintamaneni S, Patel AM, Pegram SB, Patel H, Roppelt H. Dramatic response to infliximab in refractory neurosarcoidosis. Ann Indian Acad Neurol. 2010;13(3):207-10. Class IV evidence.
57. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127(3):1064-71. Class IV evidence.
58. Nozaki K, Silver RM, Stickler DE, Abou-Fayssal NG, Giglio P, Kamen DL, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci. 2011;342(5):352-5.
59. Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol. 1998;55(9):1248-54. Class IV evidence.
60. Bihan H, Christozova V, Dumas JL, Jomaa R, Valeyre D, Tazi A, et al. Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine. 2007;86(5):259-68.
61. Kang S, Suh JH. Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiat Oncol Investig. 1999;7(5):309-12. Class IV evidence.
62. Menninger MD, Amdur RJ, Marcus Jr RB. Role of radiotherapy in the treatment of neurosarcoidosis. Am J Clin Oncol. 2003;26(4):e115-8. Class IV evidence.
63. Stelzer KJ, Thomas Jr CR, Berger MS, Spence AM, Shaw CM, Griffin TW. Radiation therapy for sarcoid of the thalamus/posterior third ventricle: case report. Neurosurgery. 1995;36(6):1188-91. Class IV evidence.